Breaking News Instant updates and real-time market news.

VRX

Valeant

$13.38

-0.09 (-0.67%)

, MYL

Mylan

$38.15

-0.5 (-1.29%)

10:22
05/19/17
05/19
10:22
05/19/17
10:22

Valeant falls to lows of day after Mylan wins IPR challenge of Apriso patent

Valeant (VRX) shares are down 24c, or 1.8%, to $13.23 after the USPTO posted the text of its decision in the inter partes review of patent no. 8,865,688 related to the drug.

VRX

Valeant

$13.38

-0.09 (-0.67%)

MYL

Mylan

$38.15

-0.5 (-1.29%)

  • 19

    May

  • 22

    May

  • 06

    Jun

  • 24

    Aug

  • 03

    Sep

  • 09

    Oct

VRX Valeant
$13.38

-0.09 (-0.67%)

05/19/17
DBAB
05/19/17
NO CHANGE
Target $18
DBAB
Hold
Deutsche Bank 'warming up' to Valeant story
In a research note titled "Warming up to VRX," Deutsche Bank analyst Gregg Gilbert says that while Valeant Pharmaceuticals is "not out of the woods," the worst fears may be subsiding. The analyst continues to view the company's near-term setup as "encouraging." Valeant's 2017 outlook seems reachable, asset sales in the near- and medium-term seem likely, and the recent refinancing provided more time and flexibility for the company to deal with its issues, Gilbert tells investors. He also believes the worst case for Xifaxan of near-term generic competition "seems to be off the table for now." The analyst keeps a Hold rating on Valeant with an $18 price target. The drugmaker closed yesterday up 22c to $13.47.
05/11/17
WELS
05/11/17
NO CHANGE
Target $9
WELS
Underperform
Valeant estimates reduced on weakening fundamentals at Wells Fargo
Wells Fargo analyst David Maris said the reaction to Valeant's guidance is too positive and notes leverage has increased, most businesses missed his forecasts, and the increase in EBITDA guidance was due to changes in how it accounts for foreign exchange. The analyst lowered estimates and reiterated his Underperform rating given the company's deteriorating fundamentals, adding that he expects the recent share strength to be temporary. However, he increased his price target on the shares to $9 from $8, noting Valeant's Q1 showed a "dramatic decline" in working capital.
05/09/17
JPMS
05/09/17
NO CHANGE
JPMS
Neutral
Valeant's road to recovery remains long, says JPMorgan
JPMorgan analyst Chris Schott finds today's rally in Valeant Pharmaceuticals unsurprising as EBITDA guidance was raised following significant cuts over the past year. That said, the analyst continues to see a "long road to recovery for the story." He keeps a Neutral rating on the shares. Valeant is up 18%, or $1.79, to $11.50 in midday trading.
05/09/17
WELS
05/09/17
NO CHANGE
WELS
Underperform
Valeant key products continue to underperform, says Wells Fargo
Following the company's Q1 results, Wells Fargo analyst David Maris says Valeant Pharmaceuticals' key products continue to underperform. Valeant's decision to highlight in its press release the EBITDA raise of 1.3% is understandable, as this is better than the recent trend, but the $50M raise is relative to approximately $28.9B of total debt, Maris tells investors in a research note. Key products and areas such as Xifaxan and Bausch + Lomb continue to underperform, the analyst contends. He keeps an Underperform rating on Valeant with an $8 price target. The stock in morning trading is up 15%, or $1.48, to $11.19.
MYL Mylan
$38.15

-0.5 (-1.29%)

05/10/17
WELS
05/10/17
NO CHANGE
Target $40
WELS
Market Perform
Mylan deals masking 'weak' organic sales, says Wells Fargo
Wells Fargo analyst David Maris believes Mylan's deals are masking the company's contracting organic growth. When excluding deals, Mylan's total third party sales declined approximately 4% in Q1, with North American Sales down 11%, Europe down 1% and Rest of World up 11%, Maris tells investors in a post-earnings research note. He believes Mylan this morning reported an essentially in-line quarter on earnings, but that organic sales were "weak," particularly in North America. Maris has a Market Perform rating on Mylan with a $40 price target.
05/01/17
BMOC
05/01/17
INITIATION
Target $50
BMOC
Outperform
Mylan initiated with an Outperform at BMO Capital
BMO Capital analyst GaryNachman started Mylan with an Outperform rating and $50 price target. The company is one of the best positioned to navigate through the challenging generic trends over the longer term, the analyst argues.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Novartis results highlight tough pricing environment, says Wells Fargo
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
04/11/17
WELS
04/11/17
NO CHANGE
WELS
Market Perform
Wells unsure of risk to Mylan from FDA warning letter
Wells Fargo analyst David Maris says he does not know what products, if any, are manufactured at Mylan's India-based plant that received the warning letter from the FDA. As such, the letter may have little or no immediate commercial risk, Maris tells investors in an intraday research note. The analyst questions whether the FDA will stop letting drugs from this facility into the U.S. He adds that to him, "nothing is more critical for a brand or generic drug company than being able to ensure that its products are safe and effective." Maris keeps a Market Perform rating on Mylan.

TODAY'S FREE FLY STORIES

JUNO

Juno Therapeutics

$23.30

-2.22 (-8.70%)

18:11
05/26/17
05/26
18:11
05/26/17
18:11
Hot Stocks
Juno Therapeutics director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

18:06
05/26/17
05/26
18:06
05/26/17
18:06
Hot Stocks
UnitedHealth's OptumHealth awarded $200.5M government contract »

UnitedHealth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VEC

Vectrus

$29.62

0.02 (0.07%)

17:56
05/26/17
05/26
17:56
05/26/17
17:56
Hot Stocks
Vectrus Systems awarded $212.03M modification to government contract »

Vectrus Systems was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMY

Imprimis

$3.34

-0.06 (-1.76%)

17:52
05/26/17
05/26
17:52
05/26/17
17:52
Syndicate
Breaking Syndicate news story on Imprimis »

Imprimis files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRCP

IRSA Propiedades Comerciales

$43.58

-0.33 (-0.75%)

17:51
05/26/17
05/26
17:51
05/26/17
17:51
Syndicate
Breaking Syndicate news story on IRSA Propiedades Comerciales »

IRSA Propiedades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSKE

Daseke

$9.79

-0.11 (-1.11%)

17:44
05/26/17
05/26
17:44
05/26/17
17:44
Syndicate
Breaking Syndicate news story on Daseke »

Daseke files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECYT

Endocyte

$2.47

0.02 (0.82%)

, RNN

Rexahn

$4.04

0.09 (2.28%)

17:35
05/26/17
05/26
17:35
05/26/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Endocyte (ECYT),…

ECYT

Endocyte

$2.47

0.02 (0.82%)

RNN

Rexahn

$4.04

0.09 (2.28%)

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

ECYT

Endocyte

$2.47

0.02 (0.82%)

17:33
05/26/17
05/26
17:33
05/26/17
17:33
Hot Stocks
Endocyte to announce updated data on EC1456, EC1169 at ASCO »

Endocyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

PEP

PepsiCo

$117.91

0.38 (0.32%)

17:30
05/26/17
05/26
17:30
05/26/17
17:30
Periodicals
PepsiCo in talks to acquire Vita Coco owner All Market, Reuters reports »

PepsiCo is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCOV

Brightcove

$6.25

0.25 (4.17%)

17:25
05/26/17
05/26
17:25
05/26/17
17:25
Hot Stocks
Breaking Hot Stocks news story on Brightcove »

ESW Capital reports 8.08%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

SHIP

Seanergy Marine

$0.69

0.001244 (0.18%)

17:19
05/26/17
05/26
17:19
05/26/17
17:19
Hot Stocks
Seanergy Marine receives Nasdaq notice »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.93

0.07 (0.64%)

, DB

Deutsche Bank

$18.46

-0.39 (-2.07%)

17:10
05/26/17
05/26
17:10
05/26/17
17:10
General news
S&P advances to end week at record as Fed signals no rush to normalize policy »

The S&P 500 (SPX)…

F

Ford

$10.93

0.07 (0.64%)

DB

Deutsche Bank

$18.46

-0.39 (-2.07%)

BBY

Best Buy

$58.97

-2.28 (-3.72%)

HPQ

HP Inc.

$18.47

0.1 (0.54%)

BX

Blackstone

$32.58

0.11 (0.34%)

NOK

Nokia

$6.38

-0.02 (-0.31%)

AAPL

Apple

$153.61

-0.26 (-0.17%)

GM

General Motors

$33.07

0.47 (1.44%)

HUN

Huntsman

$24.75

-0.11 (-0.44%)

BF.A

Brown-Forman, also tag with BFA, BFB

$52.49

-0.21 (-0.40%)

BF.B

Brown-Forman, also tag with BFA, BFB

$51.73

0.13 (0.25%)

STZ

Constellation Brands

$180.93

0.79 (0.44%)

LOW

Lowe's

$80.91

-0.42 (-0.52%)

TIF

Tiffany

$86.18

0.36 (0.42%)

SHLD

Sears

$7.78

-0.7 (-8.25%)

SIG

Signet Jewelers

$49.31

-0.99 (-1.97%)

COST

Costco

$177.86

3.13 (1.79%)

ANF

Abercrombie & Fitch

$13.22

-0.83 (-5.91%)

AEO

American Eagle

$11.50

0.08 (0.70%)

EXPR

Express

$7.85

0.03 (0.38%)

TTWO

Take-Two

$77.07

-1.46 (-1.86%)

AZO

AutoZone

$615.62

8.28 (1.36%)

DSW

DSW

$16.73

-0.06 (-0.36%)

INTU

Intuit

$138.56

0.2 (0.14%)

PBYI

Puma Biotechnology

$79.75

1.7 (2.18%)

CHS

Chico's

$9.37

-0.39 (-4.00%)

SPLS

Staples

$8.98

-0.08 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 01

    Jun

  • 01

    Jun

  • 01

    Jun

  • 02

    Jun

  • 06

    Jun

  • 06

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 20

    Jun

  • 28

    Jun

  • 21

    Jul

BGNE

BeiGene

$37.42

-0.04 (-0.11%)

17:07
05/26/17
05/26
17:07
05/26/17
17:07
Syndicate
Breaking Syndicate news story on BeiGene »

BeiGene files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

CGI

Celadon Group

17:06
05/26/17
05/26
17:06
05/26/17
17:06
Hot Stocks
Breaking Hot Stocks news story on Celadon Group »

Litespeed Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRD

Crawford & Company Inc.

, CRDA

Crawford & Co.

$7.65

0.01 (0.13%)

17:05
05/26/17
05/26
17:05
05/26/17
17:05
Hot Stocks
Crawford & Company COO Robinson to leave company »

Crawford & Company…

CRD

Crawford & Company Inc.

CRDA

Crawford & Co.

$7.65

0.01 (0.13%)

CRDB

Crawford & Company

$9.08

-0.02 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEAS

SeaWorld

$18.08

-0.13 (-0.71%)

17:03
05/26/17
05/26
17:03
05/26/17
17:03
Hot Stocks
Breaking Hot Stocks news story on SeaWorld »

Hill Path Capital raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMRC

Digimarc

$36.10

2.45 (7.28%)

17:03
05/26/17
05/26
17:03
05/26/17
17:03
Syndicate
Breaking Syndicate news story on Digimarc »

Digimarc files $100M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 06

    Sep

IPCI

Intellipharmaceutics

$1.94

-0.01 (-0.51%)

17:01
05/26/17
05/26
17:01
05/26/17
17:01
Syndicate
Breaking Syndicate news story on Intellipharmaceutics »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GWR

Genesee & Wyoming

$66.47

0.91 (1.39%)

16:57
05/26/17
05/26
16:57
05/26/17
16:57
Hot Stocks
Genesee & Wyoming CEO Hellmann named chairman of the board »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZG

Paramount Gold Nevada

$1.61

0.02 (1.26%)

16:54
05/26/17
05/26
16:54
05/26/17
16:54
Syndicate
Breaking Syndicate news story on Paramount Gold Nevada »

Paramount Gold Nevada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

16:53
05/26/17
05/26
16:53
05/26/17
16:53
Syndicate
Breaking Syndicate news story on Sangamo »

Sangamo files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

16:49
05/26/17
05/26
16:49
05/26/17
16:49
Syndicate
Breaking Syndicate news story on TG Therapeutics »

TG Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

AVXL

Anavex

$5.88

-0.06 (-1.01%)

16:49
05/26/17
05/26
16:49
05/26/17
16:49
Syndicate
Breaking Syndicate news story on Anavex »

Anavex files to sell 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIG

Employers Holdings

$39.95

-0.4 (-0.99%)

16:42
05/26/17
05/26
16:42
05/26/17
16:42
Syndicate
Breaking Syndicate news story on Employers Holdings »

Employers Holdings files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNN

Rexahn

$4.04

0.09 (2.28%)

16:41
05/26/17
05/26
16:41
05/26/17
16:41
Syndicate
Breaking Syndicate news story on Rexahn »

Rexahn files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.